



IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

March 18, 2025

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- [IN8bio, Inc.](#) (**Nasdaq: INAB**), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that the Company will participate in multiple sessions at the [Immuno-Oncology 360°](#) (IO360°) Conference 2025, held March 24-26, 2025, in Boston, MA.

William Ho, Chief Executive Officer and co-founder of IN8bio, will be Co-Chairing Day 2 of the conference starting at 8:15 AM EDT on March 25, 2025. He will deliver the welcoming remarks and discuss, "*Tackling the Tough Questions in IO for Autoimmunity Disease*." After, he will Chair the session, "*State of the IO Market, Investments and Deals Plenary*."

During the afternoon session, at 4:35 PM EDT, Mr. Ho will present on the topic of "*Picking our Horse in the Race for Autoimmunity: The Gamma-Delta T cell Engager*," and provide a corporate overview of IN8bio's recently announced INB-619, T cell engager program for oncology and autoimmune diseases.

As co-chair and panelist, Mr. Ho expects to discuss the rationale and promise of a gamma-delta T cell engager in addressing autoimmunity, a rapidly emerging frontier for immunotherapies.

Presentation and Panel Details

Co-Chairs' Welcome & Tackling the Tough Questions in IO for Autoimmunity Disease

- Date/Time: March 25, 2025, at 8:15 AM EDT

Picking Our Horse in the Race for Autoimmunity: The Gamma-Delta T Cell Engager

- Date/Time: March 25, 2025, at 4:35 PM EDT

For those interested in coordinating a time to meet with the IN8bio during IO360°, please email glenn@z3bio.com.

For more information about the event, visit <https://io360summit.com>.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program, INB-100, is focused on acute myeloid leukemia evaluating haplo-matched allogeneic gamma-delta T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI gamma-delta T cells, in combination with standard of care, for glioblastoma, and advancing novel gamma-delta T cell engagers for potential oncology and autoimmune indications. For more information about IN8bio, visit www.IN8bio.com.

Investors & Company Contacts:

Glenn Schulman, PharmD, MPH
203.494.7411
glenn@z3bio.com

IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com

Media Contact:

Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com